The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma by Poulsen, Sidsel Højklint et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
The prognostic value of FET PET at radiotherapy planning in newly diagnosed
glioblastoma
Poulsen, Sidsel Højklint; Urup, Thomas; Grunnet, Kirsten; Christensen, Ib Jarle; Larsen,
Vibeke Andrée; Jensen, Michael Lundemann; Af Rosenschöld, Per Munck; Poulsen, Hans
Skovgaard; Law, Ian
Published in:
European Journal of Nuclear Medicine and Molecular Imaging
DOI:
10.1007/s00259-016-3494-2
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Poulsen, S. H., Urup, T., Grunnet, K., Christensen, I. J., Larsen, V. A., Jensen, M. L., ... Law, I. (2017). The
prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma. European Journal of
Nuclear Medicine and Molecular Imaging, 44(3), 373-381. https://doi.org/10.1007/s00259-016-3494-2
Download date: 03. Feb. 2020
ORIGINAL ARTICLE
The prognostic value of FET PET at radiotherapy planning
in newly diagnosed glioblastoma
Sidsel Højklint Poulsen1,2 & Thomas Urup1,3 & Kirsten Grunnet1,3 &
Ib Jarle Christensen5 & Vibeke Andrée Larsen6 & Michael Lundemann Jensen3,4 &
Per Munck af Rosenschöld3,4 & Hans Skovgaard Poulsen1,3 & Ian Law2
Received: 4 May 2016 /Accepted: 10 August 2016 /Published online: 23 August 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract
Background Glioblastoma patients show a great variability in
progression free survival (PFS) and overall survival (OS). To
gain additional pretherapeutic information, we explored the
potential of O-(2-18F-fluoroethyl)-L-tyrosine (FET) PET as
an independent prognostic biomarker.
Methods We retrospectively analyzed 146 consecutively
treated, newly diagnosed glioblastoma patients. All patients
were treated with temozolomide and radiation therapy (RT).
CT/MR and FET PETscans were obtained postoperatively for
RT planning. We used Cox proportional hazards models with
OS and PFS as endpoints, to test the prognostic value of FET
PET biological tumor volume (BTV).
Results Median follow-up time was 14 months, and median
OS and PFS were 16.5 and 6.5 months, respectively. In the
multivariate analysis, increasing BTV (HR = 1.17, P<0.001),
poor performance status (HR = 2.35, P < 0.001), O(6)-
methylguanine-DNA methyltransferase protein status
(HR=1.61, P=0.024) and higher age (HR=1.32, P=0.013)
were independent prognostic factors of poor OS. For poor
PFS, only increasing BTV (HR=1.18; P=0.002) was prog-
nostic. A prognostic index for OS was created based on the
identified prognostic factors.
Conclusion Large BTVon FET PET is an independent prog-
nostic factor of poor OS and PFS in glioblastoma patients.
With the introduction of FET PET, we obtain a prognostic
index that can help in glioblastoma treatment planning.
Keywords Glioblastoma . FETPET .Biomarker . Prognostic
index . Radiation therapy
Abbreviations
BTV Biological tumor volume
CTV Clinical target volume
FET O-(2-18F-fluoroethyl)-L-tyrosine
FLAIR Fluid attenuation inversion recovery
Gd +
MRIvol
Contrast enhancing tumor volume on T1-
weighted RT planning MRI
GTV Gross tumor volume
IDH1 Isocitrate dehydrogenase 1
MGMT O(6)-methylguanine-DNA methyltransferase
PET Positron emission tomography
PS Performance status
PTV Planning target volume
RANO Response assessment in neurooncology
RT Radiation therapy
TBR Tumor-to-background ratio
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Introduction
Glioblastoma is the most common and aggressive primary
brain tumor in adults. Despite standard treatment consisting
of maximal surgical resection, radiation and chemotherapy
with temozolomide, the prognosis is poor, with a median over-
all survival (OS) of less than 15 months and 5-year OS of less
than 10 % [1]. OS and progression free survival (PFS) vary
greatly among glioblastoma patients and less than a third of
patients complete the full 6 cycles of adjuvant temozolomide
treatment [2]. Given that the chemo-radiation treatment time
constitutes a considerable fraction of the expectedOS for most
patients, it is of great interest to stratify patients by the identi-
fication of prognostic and predictive biomarkers. For instance,
a recent study found that in elderly and frail patients, a short-
course radiation therapy or temozolomide alone represent a
viable alternative. Further, for elderly patients, the standard
6-week radiotherapy regimen seemed to be associated with
substantial risk of morbidity and discontinuation [3]. Former
studies on prognostic factors for glioblastoma patients treated
with standard therapy suggests that age, O(6)-methylguanine-
DNA methyltransferase (MGMT) protein status, use of corti-
costeroids and performance status are associated with OS [2,
4, 5]. Mode of surgical resection has also been suggested as a
prognostic factor indicating that increasing postoperative re-
sidual tumor volume is associated with poor prognosis.[1]
Recently, the response assessment in neurooncology
(RANO) working group has presented their recommendations
for the clinical use of PET scans for diagnosis and treatment
evaluation in the clinical management of gliomas [6]. One of
the most promising radiotracers for glioblastoma evaluation is
O-(2–18 F-fluoroethyl)-L-tyrosine (FET) with an excellent
tumor-to-background contrast [7]. Studies have shown that
the FET PET-defined tumor volume, termed biological tumor
volume (BTV), reflects brain tumor tissue more accurately
than morphological imaging techniques like magnetic reso-
nance imaging (MRI) [8, 9]. Recently, two prospective studies
demonstrated that the absence of postoperative FET PET trac-
er uptakewas associated with a significantly longer survival in
GBM patients, while residual tumor volume on MRI was not
[4, 10]. These studies, in addition to a few other small sample-
sized studies [4, 5, 10, 11] indicate the value of postoperative,
preirradiation tumor volume on FET PET as a prognostic
factor.
Accordingly, the aim of this study was to evaluate the
prognostic value of postoperative, preirradiation FET PET in
a large cohort of patients treated with standard treatment in
order to improve the existing prognostic models for glioblas-
toma patients.
Methods
Patients
This study retrospectively evaluated 146 glioblastoma patients
diagnosed in the period September 2011 – April 2014. All
patients includedwere histologically verified glioblastoma pa-
tients [12]. They received radiation therapy (RT) with con-
comitant and adjuvant temozolomide (TMZ) as first-line treat-
ment and received a postoperative FET PETscan as part of the
RT planning 2–3 weeks postoperatively. Of the glioblastoma
patients diagnosed in this period, 200 patients received RTand
TMZ, and of these patients, 148 received a FET PETscan. No
apparent reason for the selection was found. Two patients
were excluded because of significant perioperative co-mor-
bidities, one due to meningitis and one due to a large infarc-
tion. All patients had a minimum clinical follow-up period of
1 year. The date of last follow-up was April 13th 2015.
Permission for data collection was given from the Danish
Data Protection Agency (2006-41-6979).
Histologic analysis
Evaluations were made on formalin-fixed paraffin-embedded
tissue. Tumor tissue was classified and graded as glioblastoma
according to WHO guidelines [12].
Protein status of MGMT and isocitrate dehydrogenase 1
(IDH1) were evaluated based on immunohistochemical pro-
cedures by the pathologist at time of diagnosis. Staining of
more than 10 % was considered positive for MGMT protein.
Imaging
MRI 72 h postoperatively and for RT planning was carried out
2–3 week postoperatively and with 2 days of FET PET scan-
ning on a 1.5-Tesla MRI scanner (Siemens, Erlangen,
Germany) with acquisition of standard clinical sequences in-
cluding 3D T1 (MPRAGE ) pre- and post-administration of
gadolinium contrast and T2 fluid attenuation inversion recov-
ery (FLAIR) [13, 14].
FET PET and CT scanning were performed 2–3 weeks
postoperatively as part of the RT planning procedure in a
single session using an integrated hybrid PET/CT system
scanner (Siemens Biograph mCT, Erlangen, Germany) ac-
quiring a single static FET PET frame acquired 20 to 40 min
after i.v. injection of 200 MBq FET. At our institution, a
threshold with a tumor-to-background ratio (TBR) of 1.6 is
used for radiotherapy planning, based on a biopsy-controlled
study showing 1.6 TBR as the optimal threshold for
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distinguishing between tumor and non-tumor tissue in treat-
ment naïve glioma patients [15]. However, resection may in-
duce reactive astroglioses [16] with increased FET accumula-
tion supporting a more conservative TBR of 2.0 and 1.8 for
pretreated glioma and long-term measurement, respectively
[4, 17, 18]. Since the optimal threshold for tumor delineation
is uncertain in early postoperative patients, we defined the
BTV based on activity above three different TBR cut-offs:
1.6, 1.8, and 2.0. The mean (TBRmean) and maximum
(TBRmax) TBR ratios were calculated by dividing the mean
and maximum values of the lesion by the mean activity in
healthy appearing gray and white matter [13, 14] (See
Appendix for details).
Treatment
Prior to radio-chemotherapy, all patients received either a ste-
reotactic biopsy or partial or gross total surgical tumor resec-
tion. As primary postsurgical treatment, all patients received
6 weeks of concomitant RT/TMZ therapy, with TMZ 75 mg/
m2/day and RT at a dose of 60 Gy to the planning target
volume based on both MR and FET PET imaging in 30 frac-
tions, 5 fractions per week [13, 14, 19].
To relieve neurological symptoms, a number of patients
were given corticosteroids. In this study, we considered a cor-
ticosteroid dosage of less than 15 mg a day at RT/TMZ treat-
ment initiation as phasing out and, therefore, registered it as no
use of corticosteroids. Four weeks after completion of con-
comitant RT/TMZ therapy, patients were given up to six
courses of adjuvant TMZ therapy, one course defined as
TMZ for 5 days followed by 23 days without therapy. The
initial course was given at a dose of 150 mg/m2/day and the
remaining courses at a dose of 200 mg/m2/day. The dose was
adjusted based on relevant blood tests.
Radiation treatment planning
Treatment planning for RTwas performed three dimensionally
by fusing cerebral CTwith a 1-mm slice thickness with base-
line MRI and FET PET on the EclipseTM treatment planning
system (Varian Medical Systems, Palo Alto, CA, USA).
Volumes of interest were defined in agreement with
Internat ional Commission on Radiat ion Units &
Measurements Reports 50 and 62. The gross tumor volume
(GTV) was defined as the contrast-enhanced tumor on
postcontrast T1 image on the baseline MRI scan. The clinical
target volume (CTV) was defined as the GTV+2 cm margin,
and the FET PET BTV (>1.6 B) without additional margin, if
this extended outside the CTV. In a previous publication, we
showed that FET PET will increase the CTV compared to
CTV(MRI) in approximately 11 % of patients with glioblas-
toma [13]. If present, the surgical cavity was included. The
PTV was defined as the CTV+0.5 cm margin for patient
setup inconsistencies. Tolerance doses for organs at risk were
as described [13]. During RT, patients were also given antibi-
otic prophylaxis with 400 mg sulfamethoxazole and 80 mg
trimethoprim 3 times per week.
To obtain a volumetric measure of the MRI contrast en-
hancing residual tumor within the MRI GTV as defined by
an oncoradiologist, we used a three dimensional (3D)
isocontouring threshold-based method on the post-contrast
T1 RT planning MRI in MIRADA software (version XD3.4,
Mirada Medical Ltd, New Road, Oxford, UK). This method
excluded the resection cavity and all cystic/necrotic areas.
Furthermore, high intensity changes related to hemorrhage
or infarcts were removed with reference to the apparent diffu-
sion coefficient MRI sequences. All volumes were defined
blinded to the FET PET scanning. The residual MRI tumor
volume was set to 0 mL in all patients evaluated to have gross
total resection on early postoperative MRI.
Clinical evaluation
Patients who underwent resection were evaluated by an expe-
rienced neuroradiologist (V.A.L) with a postoperative MRI
scan 48 – 72 h after surgery. During treatment, patients were
evaluated with MRI scans and neurological and clinical per-
formance after two and five courses of adjuvant TMZ. After
treatment, patients were followed with the same procedures
every 3 months until death.
Study endpoints
Study endpoints were OS and PFS) OS was defined as time
from start of RT/TMZ treatment until death from any cause.
PFS was defined as time from start of RT/TMZ until first
occurrence of disease progression [20] or death.
Statistical considerations
The Cox proportional hazards model was used for univariate
and multivariate analysis of PFS and OS. Model assessment
was done using cumulative sums of martingales. The BTVon
FET PET and the contrast-enhancing tumor volume on T1
weighted RT planning MRI (Gd + MRIvol) were scored as
continuous covariates and hazard ratios (HRs) are presented
for a 10-unit (cm3) difference. The survival probabilities for
OS at 6, 12 and 18 months as a function of the BTV were
estimated from the survivor function estimate derived from
the Cox analysis. To investigate correlations between the three
TBR cut-off thresholds prior to entry into prognostic models,
we used Pearson’s correlations. Calculations were performed
using SAS (v9.4, SAS Institute, Cary, NC, USA) and R (R
Development Core Team, Vienna, Austria, http://www.R-
project.org). P values less than 0.05 were considered
significant.
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Screened factors
The following factors were screened in univariate analysis:
TBRmean, TBRmax, BTV (1.6), BTV (1.8), BTV (2.0), multi-
focal disease, gender, Gd + MRIvol, frontal location, MGMT
protein status, IDH1, PS, use of corticosteroids and age.
Results
Patient characteristics
We included 146 patients (50 women and 96 men) in the
cohort. Patient’s demographics are summarized in Table 1
(for a complete presentation of patient data see online research
table S1). For second-line treatment, patients received: pallia-
tive TMZ (7.5 %), bevacizumab in combination with
irinotecan (30.1 %), bevacizumab in combination with
lomustine (5.5 %), monotherapy with lomustine (0.7 %), var-
ious protocolled experimental treatments (9.6%), reirradiation
(2.8%), RTand concomitant TMZ in contralateral hemisphere
(0.7 %).
The median BTV measured with a TBR > 1.6 was
21.8 cm3, TBR > 1.8 was 10.5 cm3 and TBR > 2.0 was
5.4 cm3. At the end of study follow-up, 49 patients were still
alive and of these, 16 patients were still alive without progres-
sion. Median follow-up time was 14 months with a median
OS and PFS of 16.5 months and 6.5 months, respectively.
Univariate analyses
In univariate analyses, factors significantly associated with
poor OS (online research table S2) were larger BTV (for all
three TBR’s P<0.001), higher TBRmean (P<0.001), higher
TBRmax (P<0.001), older age (P=0.002), WHO PS 1 vs. 0
(P < 0.001), WHO PS 2 vs. 0 (P < 0.001), use of
corticosteroids≥15 mg (P=0.001), MGMT protein-positive
(P<0.001) and contrast-enhancing tumor volume on MRI
(P<0.001).
Factors associated with poor PFS were (online research
table S2) larger BTV (P < 0.001), higher TBRmean
(P<0.001), higher TBRmax (P<0.001), WHO PS 1 vs. 0
(P = 0.004), use of corticosteroids > 15 mg (P = 0.04),
MGMT protein-positive (P=0.006). Contrast-enhancing tu-
mor volume on MRI was not a significant prognostic factor
(P=0.082).
A Pearson correlations test showed a very strong correla-
tion (p<0.0001) between BTV delineated with the three dif-
ferent tumor thresholds. The correlations coefficients were:
1.6 vs. 1.8: r = 0.99; 1.6 vs. 2.0: r = 0.96; 1.8 vs. 2.0: r = 0.99.
A Mann–Whitney U test showed a strong correlation be-
tween the use of corticosteroids and both PS (P<0.0001) and
BTV (P=0.005).
Multivariate analysis
All three BTV delineated with different activity thresholds
were strongly correlated and all were significantly associated
with OS and PFS in univariate analyses. We found no obvious
advantage of a more conservative threshold for prognostic
evaluation. Thus, for the multivariate model, we used a BTV
based on a TBR>1.6 B which is already used in our standard
clinical practice for RT planning. Due to a small sample size of
the PS 2 group, PS 2 vs. PS 0 was insignificant when included
in the multivariate model. In order to adjust for PS and to
Table 1 Patient characteristics
Population (n = 146)
Gender, n (%)
Female 50 (34.2)
Male 96 (65.8)
Age (years), median (range) 60 (26–79)
WHO performance status, n (%)
0 81 (55.5)
1 56 (38.4)
2 9 (6.2)
Glioblastoma diagnosis, n (%)
Glioblastoma 143 (97.9)
Secondary glioblastomaa 3 (2.1)
Multifocal disease, n (%)
Yes 18 (12.3)
No 128 (87.7)
Frontal location, n (%)
Yes 39 (26.7)
No 107 (73.3)
Use of corticosteroids≥ 15 mg/d, n (%)
Yes 74 (50.7)
No 72 (49.3)
Corticosteroid dose (mg), median (range) 15.0 (0–112.5)
Nr series adj. temozolomide, n (%)
0 10 (6.8)
1 6 (4.1)
2 41 (28.1)
3 9 (6.2)
4 7 (4.8)
5 18 (12.3)
6 53 (36.3)
> 6 2 (1.4)
MGMT protein, n (%)
Positive 48 (32.9)
Negative 98 (67.1)
Gd + MRIvol (cm3), median (range) 8.7 (0.0–122.4)
OS (months), median 16.46
PFS (months), median 6.54
TBRmean, median (range) 1.92 (0.0–3.0)
TBRmax, median (range) 2.92 (0.0–6.94)
BTV > TBR of 1.6 (cm3), median (range) 21.77 (0.0–154.86)
BTV > TBR of 1.8 (cm3), median (range) 10.53 (0.0–127.15)
BTV > TBR of 2.0 (cm3), median (range) 5.36 (0.0–105.52)
a Prior anaplastic astrocytoma or other histology progressing to grade IV
glioma
b Evaluated on 48–72 h postoperative MRI
Abbreviations: MGMT = O(6)-methylguanine-DNA methyltransferase,
OS = overall survival, PFS = progression free survival, TBR = tumor-to-
background ratio, BTV = biological tumor volume, Gd + MRIvol =
contrast-enhancing tumor volume on T1-weighted RT planning MRI
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simplify the model, the two groups, PS 1 and PS 2, were
pooled for the final multivariate analysis.
In the multivariate analysis (Table 2), factors associated
with poor OS were larger BTV (per 10 cm3 HR = 1.17,
95 % CI: 1.07–1.27, P<0.001), poor PS (HR=2.35, 95 %
CI: 1.54–3.59, P < 0.001), MGMT protein-positive
(HR=1.61, 95 % CI: 1.07–2.42, P=0.024), and higher age
(per decade HR=1.32, 95 % CI: 1.06–1.63, P=0.013). Gd +
MRIvol was not prognostic of OS (P=0.72). For PFS, only
larger BTV (HR=1.18, 95%CI: 1.07–1.31, P=0.002) was of
significant prognostic value.
However, in an independent multivariate analysis without
BTV, Gd + MRIvol was prognostic of OS (HR=1.15, 95 %
CI: 1.05–1.25, P=0.003) but not of PFS (Table 2). The cor-
relation between Gd + MRIvol and BTV was r = 0.67
(p<0.0001), r2 = 0.45 with a slope on linear regression of
0.41 (95 % CI: 0.33–0.48; Fig. 1).
Prognostic index
Based on significant factors from the multivariate analysis, we
defined a prognostic index model where the survival probabili-
ties at 6, 12 and 18 months can be estimated as a function of the
BTV (TBR>1.6 B).We divided patients into prognostic groups
based on age, MGMT protein status and PS. The prognostic
value of BTV FET PET at 6 and 18 months in the worst and
best prognostic group is visualized in Fig. 1. For all groups and
12-month survival, see online research figure S2. As seen in
Fig. 2, a patient in a good prognostic group (Age 50, MGMT
protein negative, PS 0) with a BTVof 10 cm3 has a 77% chance
at being alive at 6 months, whereas a patient in the poor prog-
nostic group (Age 70, MGMT protein positive, PS 1-2) with at
BTVof 120 cm3 has an 18 % chance at being alive at 6 months.
Discussion
This retrospective study is, to date, the largest standard-
ized published series evaluating the prognostic value of
FET PET scanning postoperatively in a multivariate set-
ting in glioblastoma patients. We found that BTV, re-
gardless of which of three different activity cut-off
thresholds was used, together with PS, MGMT protein
and age were strong independent prognostic factors for
OS. For poor PFS, increasing BTV and poor perfor-
mance status were prognostic. The rationale behind the
higher thresholds applied in previous studies [4, 11]
adhere to the increased non-specific FET uptake in re-
gional reactive astrogliosis following surgical trauma
[21–23], but could also underestimate clinically signifi-
cant gliomatose infiltration (Fig. 3). The strong correla-
tion between the three BTV thresholds indicates that for
a statistical and prognostical evaluation, there is no clear T
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advantage of one threshold over another, probably
reflecting the above trade-off between sensitivity and
specificity for tumor tissue. A previous smaller FET
PET study similarly did not find any prognostic superi-
ority of different thresholds [11]. For practical reasons,
we chose TBR > 1.6 B for the multivariate analysis
since it is already implemented in the clinic for standard
RT planning at our institution, where tumor sensitivity
is a priority. Previous studies indicate the use of differ-
ent thresholds at different stages of tumor evaluation
whether in primary diagnosis, RT planning, or in assess-
ment of recurrence or response [15, 24, 25].
TBRmean and TBRmax were associated with OS and PFS in
the univariate analysis, but failed to predict survival in the
multivariate model, similar to a previous study [4]. This is
not surprising given that FET is not metabolically fixated in
tissue and the kinetics differ between tumors [4]. As we ac-
quire images only late in the time-activity curve, these differ-
ent kinetics will increase the variability in TBRmean and
TBRmax and influence the prognostic value.
Former studies on prognostic factors for glioblastoma pa-
tients treated with standard therapy suggests that age, MGMT
protein status, use of corticosteroids and performance status are
associated with OS [2, 4, 5]. A FET PET study identified post-
operative BTVas the most important independent imaging bio-
marker prognostic for both PSF and OS irrespective of surgical
mode [4]. Our study confirms BTV, age, MGMT protein status
and performance status. In our model, positivity for MGMT
protein was found prognostic of poor OS. In this retrospective
study, polymerase chain reaction (PCR) of MGMT promotor
methylation status on the DNA level was not performed. The
evaluation of MGMT protein in the tumor cells using immuno-
histochemistry (IHC) was the diagnostic standard in glioblasto-
ma pathology during the observation period. Previously, we
have demonstrated a good agreement between MGMT
promotor methylation and MGMT protein status in a study of
151 glioblastoma patients from our institution and, therefore, we
find MGMT protein a reliable surrogate marker for MGMT
promotor methylation, at least in our hands, and that our data
and interpretation would not change should we reanalyze the
material using the PCR technique [26].
Based on the significant factors in the multivariate
model, we formulated a prognostic index using Cox
modeling for OS. The prognostic index can be used in
clinical practice to estimate survival probability of the
individual patient at 6, 12 and 18 months as a function
of BTV (Fig. 1, online research figure S2). The model
underlines the relative sensitivities of increasing BTV in
different patient populations revealing a profound disso-
ciation. Increasing BTV has a marked short-term nega-
tive impact on estimated survival probability in the poor
prognostic group. However, for the good prognostic
group, the impact of BTV is only slight on the short
term, and becomes clinically significant on the 18-
Fig. 1 Plot of tumor volumes: contrast-enhancing tumor volume on T1
MRI and biological tumor volume (BTV) on FET PET. There is a
significant correlation between contrast-enhancing tumor volume on T1
MRI (Gd + MRIvol ) and BTV on FET PET, r = 0.67, r2 = 0.45
(P < 0.0001). The slope of the curve is 0.41, indicating a systematic
underestimation of Gd + MRIvol compared to BTV. Volumes are in cm3
Fig. 2 Estimated survival
probability at 6 and 18 months as a
function of biological tumor
volume (BTV). The short-term
(6 months) impact of increasing
BTV glioblastoma patients is most
pronounced in the poor prognostic
group (b) and in the long term
(18 months) in the good prognostic
group (a). BTV is in cm3, and
derived from FET PET (>1.6 B).
Prognostic groups: A: age 50,
MGMT protein-negative, PS 0. B:
age 70, MGMT protein-positive,
PS 1–2
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month estimated survival probability. The described
prognostic model can potentially be a valuable tool in
the clinical decision process, tailoring the optimal ther-
apeutic strategy for the individual glioblastoma patient.
Thus, it could be used to identify unfortunate patients
with a life expectancy of less than 6 months, where
s t anda rd t r e a tmen t can be cons ide red fu t i l e .
Conversely, it could identify potential long-time survi-
vors, where preservation of cognitive function and qual-
ity of life is given high priority and is reflected in the
choice of therapy. It follows that the model could be
used to reduce the risk of unnecessary side effects in
both patient profiles. It should be noted that the model
in its present form should be considered hypothetical
and validation in an independent cohort prior to practi-
cal use is a prerequisite.
We found that larger BTVwas prognostic of poor PFS as in
previous studies [4, 11]. PFS is only marginally confounded
by second-line therapy, and has the benefit of offering an
earlier assessment and higher statistical power at the time of
analysis. A prolonged PFS by itself may have a clinically
significant beneficial impact on overall function and quality
of life for the glioblastoma patient given the infiltrative and
destructive nature of the disease. A recent large metaanalysis
of 91 unique glioblastoma trials has shown that PFS and OS
are strongly correlated, indicating that PFS may be an appro-
priate surrogate endpoint for OS [27].
One limitation was the use of the Macdonald criteria, but it
has been shown that PFS evaluated by both RANO and
Macdonald were associated with OS [28].
The prognostic value of postoperative BTV found in
this and in other FET PET studies [4, 10, 11] repeatedly
underlines the importance of maximal tumor resection [10,
29, 30]. We found a strong correlation between Gd +
MRIvol and the BTV (Fig. 2) with a slope significantly
lower than unity, indicating a general underestimation of
tumor volumes based on Gd + MRIvol compared to BTV.
In multivariate analysis, Gd + MRIvol did have indepen-
dent prognostic value, providing BTV was not included, in
which case it was lost. Only BTV was prognostic for PFS,
while Gd + MRIvol was not in any combination emphasiz-
ing BTV as the more important prognostic factor.
Extending the MRI tumor volume by including non-
contrast-enhancing changes on T2-weighted sequences
will not be practical on MRI 2–3 week postoperatively
because of reactive changes, including oedema, ischemia,
and gliosis, limiting the value in evaluating the extent of
surgical resection and local tumor control.
Conclusion
BTVis a strong independent prognostic factor for OS and PFS
for glioblastoma patients treated with surgery and radio-
Fig. 3 FET PET and early postoperative T1-weighted MRI. Early (48–
72 h) postoperative post-contrast T1-weighted MRI alone and fused to
FET PET scanning performed 2 weeks later for radiation treatment
planning showing examples of conflicting tumor definitions of the two
techniques. a. Residual metabolically active non-enhancing tumor
remnant anterior to the resection cavity identified in the left frontal lobe
(red arrow), presumably infiltrating glioblastoma. On MRI, the tumor
was evaluated as gross total resected. Patient ID 30. Gd + MRIvol:
0 cm3; BTV: 26 cm3; OS: 13 months. See Table S1. Top: Transaxial
section above corpus callosum. Bottom: Sagittal section left of midline.
This patient was evaluated as partially resected based on a smaller
contrast enhancing region (blue arrow) in the depth of the resection
cavity in the left temporal region. Lack of metabolic activity on FET
PET, however, suggests reactive changes. Areas of increased uptake is
found in subcortical white matter anterior and posterior to the cavity (red
arrow), presumably infiltrating glioblastoma. Patient ID 98. Gd +
MRIvol: 3.2 cm3; BTV: 7.8 cm3; alive at 31 months follow-up. See
Table S1. Top: Transaxial section at the level of mesencephalon.
Bottom: Mid-cerebellar coronal section
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chemotherapy. A model including BTV, MGMT protein sta-
tus, PS and age can estimate the probabilities of OS for glio-
blastoma patients and can, if validated, be implemented in the
clinical practice for treatment stratification.
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Appendix
PET scanning FET PET and CT scanning was performed as part of
the RT planning procedure in a single session using an integrated hybrid
PET/CT system scanner (Siemens Biograph mCT, Erlangen, Germany)
with the patient’s head positioned in a moulded plastic net fixation device
directly attached to a scanner flat-top cradle. A single static FET PET
frame was acquired 20 to 40 min after i.v. injection of 200 MBq FET. For
all images, default random, scatter, and dead time correction and low-
dose CT-based attenuation correction was applied. Image reconstruction
was performed using OSEM 3D (4 iterations, 16 subsets with a matrix
size of 336 x 336 x 74 [0.8 x 0.8 x 3mm voxel size]). Images were filtered
with a 5-mm FWHM Gaussian filter.
The FET PET image was co-registered to the T1-weighted post-gad-
olinium contrast RT planning MRI. A 3D crescent-shaped background
(B) region of interest (ROI), encompassing the activity above 70 % of
maximum, was delineated in healthy appearing gray andwhite matter of 4
contiguous brain slices above the insula in the contralateral hemisphere to
the tumor. When delineating a tumor on a FET PET scan, the exact
threshold for the metabolic activity that distinguishes between tumor
tissue and unspecific postoperative reactive changes is not well defined.
At our institution, a threshold with a tumor-to-background ratio (TBR) of
1.6 is used for radiotherapy planning, based on a preoperative biopsy-
controlled study showing 1.6 TBR as the optimal threshold for
distinguishing between tumor and non-tumor tissue [31]. Another study
found a TBR of 2.0 as the best threshold for pretreated glioma [32, 33]. A
third study used a TBR of 1.8 for long-termmeasurement [34]. Therefore,
the BTV derived from FET PET was auto-contoured in 3D, defining
tumor tissue at a threshold of above 1.6, 1.8 and 2.0 of the mean stan-
dardized uptake value (SUV) in the background ROI (Syngo-TrueD,
Siemens). TBRmean and TBRmax were calculated by dividing the mean
and maximum values of the lesion by the mean SUV B.
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